Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia

被引:68
作者
Hilker, R [1 ]
Schischniaschvili, M [1 ]
Ghaemi, M [1 ]
Jacobs, A [1 ]
Rudolf, J [1 ]
机构
[1] Univ Cologne, Neurol Klin & Poliklin, D-50924 Cologne, Germany
关键词
focal dystonia; botulinum neurotoxin type A; health related quality of life;
D O I
10.1136/jnnp.71.2.193
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives-The advent of botulinum neurotoxin type A (BoNT/A) gave rise to substantial progress in the treatment of focal dystonias. In the light of the high costs of the toxin and the necessity to establish valid outcome indices for this treatment apart from sheer reduction of dystonic muscle tone and posture, the impact of focal dystonia and its treatment with BoNT/A on patients' health related quality of life (HRQL) was determined. Methods-Fifty patients with cranial and cervical dystonia treated long term with BoNT/A were enrolled in a prospective, open labelled cohort study. The HRQL was assessed using the EuroQo1 (EQ-5D) and the short form 36 health survey questionnaire (SF-36) at baseline before BoNT/A injections and at two follow up visits after 6 and 12 weeks covering one BoNT/A treatment period with maximum effect size at the first follow up. Results-Compared with a general population sample, a considerable negative impact of focal dystonia on HRQL was found in patients under investigation. In both disease types, BoNT/A treatment led to a significant improvement in several HRQL dimensions, in particular providing moderate to marked effect sizes in the fields of mental health and pain. The impairment of HRQL due to pain as well as the BoNT/A induced improvement within this SF-36 subscore were significantly higher in patients with cervical dystonia. Under BoNT/A therapy, no correlation was found between changes of clinical outcome scores and HRQL measures. Conclusions-The data confirm that BoNT/A is able to induce a significant, but temporary amelioration of several aspects of HRQL in both types of focal dystonia. This may substantially contribute to the patients' subjective benefit from the therapy. Moreover, the data provide further arguments to accept high costs of the BoNT/A treatment in these severely handicapped patients, as a consequence of its considerable benefit on quality of life.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 27 条
[1]  
[Anonymous], MOVEMENT DISORDERS
[2]  
[Anonymous], 1993, SF 36 HLTH SURVEY
[3]   Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia [J].
Brans, JWM ;
Lindeboom, R ;
Aramideh, M ;
Speelman, JD .
NEUROLOGY, 1998, 50 (05) :1461-1463
[4]   EuroQol: The current state of play [J].
Brooks, R .
HEALTH POLICY, 1996, 37 (01) :53-72
[5]   GERMAN TRANSLATION AND PSYCHOMETRIC TESTING OF THE SF-36 HEALTH SURVEY - PRELIMINARY-RESULTS FROM THE IQOLA PROJECT [J].
BULLINGER, M .
SOCIAL SCIENCE & MEDICINE, 1995, 41 (10) :1359-1366
[6]   IDIOPATHIC CERVICAL DYSTONIA - CLINICAL CHARACTERISTICS [J].
CHAN, J ;
BRIN, MF ;
FAHN, S .
MOVEMENT DISORDERS, 1991, 6 (02) :119-126
[7]  
Fahn S., 1989, QUANTIFICATION NEURO
[8]   THE SF-36 HEALTH SURVEY QUESTIONNAIRE - AN OUTCOME MEASURE SUITABLE FOR ROUTINE USE WITHIN THE NHS [J].
GARRATT, AM ;
RUTA, DA ;
ABDALLA, MI ;
BUCKINGHAM, JK ;
RUSSELL, IT .
BMJ-BRITISH MEDICAL JOURNAL, 1993, 306 (6890) :1440-1444
[9]   DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BOTULINUM TOXIN INJECTIONS FOR THE TREATMENT OF SPASMODIC TORTICOLLIS [J].
GREENE, P ;
KANG, U ;
FAHN, S ;
BRIN, M ;
MOSKOWITZ, C ;
FLASTER, E .
NEUROLOGY, 1990, 40 (08) :1213-1218
[10]   Effect of dystonia and botulinum toxin treatment on health-related quality of life [J].
Gudex, CM ;
Hawthorne, MR ;
Butler, AG ;
Duffey, P .
MOVEMENT DISORDERS, 1998, 13 (06) :941-946